A Randomized Placebo-Controlled Double-Blind Study of Adjuvant Cemiplimab Versus Placebo after Surgery and Radiation Therapy in Patients with High Risk Cutaneous Squamous Cell Carcinoma (CSCC); R2810-ONC-1788

Brief description of study

The main purpose of this study is to determine if the study drug, Cemiplimab, will prevent cutaneous squamous cell cancer from returning after surgery and radiation. The information from this study may also be used to better understand the following additional research questions: • To see if cemiplimab may help you live for longer • To understand how study participation affects how you feel. This is sometimes called “quality of life.” • Side effects that you may experience during the study


Clinical Study Identifier: s18-01608
ClinicalTrials.gov Identifier: NCT03969004


If you are registered as a volunteer, please login to the dashboard to send referrals.